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Alteration in extracellular matrix (ECM) homeo-
stasis is a unifying concept in the development of
aneurysms. In particular, elastin fibers in specimens
from abdominal aortic aneurysms (AAAs) are
severely fragmented with only patchy distribution.1,2
The changes in the ECM involve not only the
aneurysmal aorta but also the more proximal nondi-
lated aorta,3 which indicates the systemic nature of
this disease.
Matrix metalloproteinases (MMPs) are a class of
proteolytic enzymes that are increased in patients
with AAAs.4-6 MMPs are released by inflammatory
cells and then act on the ECM. The inflammatory
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Purpose: Matrix metalloproteinases (MMPs) are proteolytic enzymes that can degrade the
extracellular matrix of the aortic wall and lead to the formation of abdominal aortic
aneurysms (AAAs). MMP inhibitors are a class of drugs that were developed to inhibit
the activity of these proteolytic enzymes and are currently being studied as a way to con-
trol inflammatory diseases and cancer metastases. In this project, BB-94 (also known as
batimastat), a specific inhibitor of MMPs, was evaluated for its ability to control
aneurysmal growth in an experimental AAA model.
Methods: Experimental AAAs were created in a standard rat model by perfusing elastase
into an isolated segment of aorta. The rats then were randomized to postoperatively
undergo treatment daily with the MMP inhibitor BB-94 or the carrier control solution.
Measurements of the aortic diameter were made at the time of initial surgery and at the
time of death on postoperative day 7. Aortic tissue was obtained for histologic exami-
nation, elastin evaluation, and MAC 1-a antibody staining to evaluate the inflammato-
ry response.
Results: The rats that underwent treatment with BB-94 had significantly less aneurysmal
dilatation and a 113% increase in aortic size, as compared with the control rats that had
a 157% increase (P = .026). Histologic examination of the harvested aortas and grading
of the elastin content showed a significantly greater elastin preservation in those rats that
were treated with BB-94 as compared with the control rats (P = .036). MAC 1-a anti-
body staining showed an attenuation of the inflammatory response in the group of rats
that underwent treatment with BB-94. Morphologic examination also revealed that the
control of the inflammatory response correlated with the areas of elastin preservation.
Conclusion: MMP inhibition with BB-94 limited the expansion of AAAs in this rat
model. BB-94 appears to work not only as a direct pharmacologic inhibitor of MMPs
but also as an interference with the inflammatory response seen in AAAs. Control of the
inflammatory response was an unexpected result and may be related to the alterations in
feedback mechanisms that are related to extracellular matrix degradation. Because this
class of drugs is presently being developed to control the MMP inflammatory response
seen with arthritis, these drugs also may ultimately serve as a pharmacologic treatment
for patients with AAAs. (J Vasc Surg 1999;29:130-9.)
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infiltrate in patients with AAAs has been correlated
with the MMP release.7-9 MMP activity is inhibited
naturally by tissue inhibitors of metalloproteinases.
The differences in activity of tissue inhibitors of me-
talloproteinases have not been consistently seen in
AAA tissue samples, and their role in the develop-
ment of aneurysms has yet to be defined.8,10,11
To better understand aneurysm development, a
rat model that mimics many of the characteristics of
human AAA development has been established.12-15
This model relies on the infusion of elastase into the
rat infrarenal aorta to initiate the process of aneurys-
mal degeneration. After the infusion, there is an
early quiescent period that is subsequently followed
by the infiltration of inflammatory cells. Tissue
analyses of the rat aorta specimens have revealed
increased activity of MMPs that correlates with the
inflammatory response.15,16
In this paper, we report on the application of a
specific broad-spectrum matrix metalloproteinase
inhibitor in an attempt to control the growth of
these experimental aneurysms. MMP inhibition by
pharmacologic agents may eventually lead to an
alternative nonsurgical management for AAAs.
METHODS
Aneurysm formation. Male Wistar rats (mean
weight, 377 ± 12.8 g [standard error of the mean];
range, 304 to 477 g) underwent elastase perfusion of
a totally isolated segment of the distal abdominal
aorta to induce infrarenal AAA formation, which is
similar to methods previously described.14,15 The ani-
mals underwent anesthesia with isoflurane inhalation-
al anesthetic. The procedures were performed in ster-
ile conditions, with the aid of a high-powered stereo-
operating microscope. The study was approved by the
Institutional Animal Care and Use Committee, and
animal care complied with the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory
Animal Resources, Commission on Life Sciences,
National Research Council. Washington: National
Academy Press, 1996).
A midline laparotomy was performed, and the
aorta below the left renal vein was dissected careful-
ly from the inferior vena cava and surrounding tis-
sues. All the lumbar arteries from this segment of
aorta were ligated. The left femoral artery was can-
nulated in the groin with a PE-10 polyethylene
catheter (VWR Scientific Products, Bridgeport, NJ).
The catheter was anchored in the distal aorta with a
tie just above the inferior mesenteric artery. A prox-
imal tie was secured around the aorta just distal to
the left renal vein. The isolated segment of aorta
JOURNAL OF VASCULAR SURGERY
Volume 29, Number 1 Bigatel et al 131
then was perfused for 2 hours with a syringe pump
(Bioanalytical Systems, West Lafayette, Ind, or
Harvard Apparatus, South Natick, Mass) with 2 mL
of a sterile saline solution that contained 25 U/mL
of type I porcine pancreatic elastase (Sigma
Chemical Company, St Louis, Mo).
At the end of the 2-hour infusion, the catheter
was removed, the femoral artery was ligated, and
flow was restored through the aorta. The wounds
were closed, and the animals were recovered from
anesthesia. Measurement of the external diameter of
the aorta was obtained with an ocular micrometer
that was attached to the operating microscope
before and after the elastase infusion.
After 24 hours, the animals were randomized in a
blinded fashion into two groups. The control group
underwent treatment for 6 days with a daily intraperi-
toneal injection of 2 mL of phosphate-buffered saline
solution with 0.01% Tween 20. The treatment group
underwent treatment with the above carrier that con-
tained a suspension of 15 mg of BB-94 (also known
as batimastat), the broad spectrum matrix metallo-
proteinase inhibitor (British Bio-technology Ltd,
Oxford, United Kingdom). This dose of BB-94 was
administered on the basis of experiments, which were
carried out by the manufacturer17 and other investi-
gators,18 that determined the maximal effective dose
for inhibition of MMP activity in rats.
On postoperative day 7, the animals underwent a
second laparotomy with the dissection of the aorta
from the surrounding tissue. A final measurement of
the aorta was made with the ocular micrometer. The
animals then were killed, and the aorta was harvested
and frozen in liquid nitrogen. Aortic specimens also
were obtained for histologic analysis by placing a
piece of the aorta immediately into 3% paraformalde-
hyde in a phosphate-buffered saline solution.
Inclusion in the study required the survival of
the animal for the entire study period and the devel-
opment of an aneurysm. Only the animals that sur-
vived the first postoperative night were entered into
the randomization process. All the animals who sur-
vived the first postoperative night survived until har-
vest. A high-flow aortocaval fistula developed in one
animal. This animal was excluded at the time of har-
vest as a result of the possible effects of significantly
altered hemodynamics on the model and was
replaced at that time with another rat that under-
went the same treatment.
Histology. Representative sections from each
aorta were obtained for histologic examination. The
specimens were stained with hematoxylin and eosin
staining, Masson staining, and Verhoeff ’s staining
methods. A comparison was made between the rats
that underwent treatment and the control rats with
regards to deviation from normal histology, inflam-
matory infiltrate, and extent of elastin degradation.
Elastin degradation was quantitated with a specif-
ic scale that we developed to compare the control and
treatment groups. The elastin degradation was esti-
mated from a microscopic inspection of the elastin-
stained tissue sections. Five independent reviewers
graded each specimen in a blinded fashion. The spec-
imens were assigned to one of the following five cat-
egories: group I, more than 99% elastin degradation;
group II, 90% to 99% elastin degradation; group III,
50% to 89% elastin degradation; group IV, 10% to
49% elastin degradation; and group V, less than 10%
elastin degradation.
The frozen sections of each aorta were stained
with monoclonal anti-rat MAC 1- a antibody
(Seikagaku Corporation, Tokyo, Japan), which iden-
tifies an integrin expressed specifically on neutrophils
and the monocyte cell line. These specimens and the
control sections were stained with a fluorescein iso-
thiocyanate–conjugated anti–immunoglobulin A sec-
ondary antibody (Sigma Chemical Company) to the
MAC 1-a antibody. A microscope with fluorescein
isothiocyanate filters was used to view the slides.
Because the aneurysmal lesions and infiltrate were
asymmetric, an overall assessment of inflammation
was made on the basis of microscopic inspection of
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histologic sections. The evaluations of inflammatory
infiltration were made on tissue sections from rats
that were randomized to treatment group and ana-
lyzed in a blinded fashion.
Data analysis. Preperfusion, postperfusion, and
final aortic diameters were measured as described
previously. Each animal was used as its own control
by calculating a relative change of the final aortic
diameter from the starting diameter. The mean
changes ± the standard error of the mean in aortic
diameters between control and treatment groups
were compared by means of the unpaired two-tailed
t test with the GraphPAD Instat software package
(GraphPAD Software, San Diego, Calif). Analysis of
the amount of elastin degradation was obtained by
means of the Cochran-Armitage test of trend with
an exact statistical method in the SAS statistical soft-
ware package (SAS Institute, Inc, Cary, NC).
RESULTS
A preliminary pilot project was carried out to doc-
ument the experience of our laboratory with the
development of AAAs after elastase infusion. A 2-hour
intra-aortic infusion of elastase produced significant
aortic dilatation that was evident 7 days after the elas-
tase infusion, which was consistent with previous
reports. In the rats that underwent elastase infusion,
the mean increase in aortic diameters at day 7 was
167% ± 8.5% of the diameter measured before infu-
sion (n = 3). This was significantly greater (P = .001)
than the 16% ± 5% increase that was measured in rats
that were infused with saline solution only (n = 2).
After the preliminary experiments were complet-
ed, the elastase perfused rats were randomly assigned
to a treatment group that underwent treatment with
the MMP inhibitor BB-94 (n = 12) or to a control
group (n = 11). The rats underwent treatment with
daily intraperitoneal injections of BB-94 or vehicle.
Randomization resulted in rats with equivalent
weights in the two groups (P > .8). The baseline aor-
tic diameter measurements also were equivalent,
with values of 1.7 ± 0.05 mm for the control group
and 1.7 ± 0.06 mm for the BB-94 group (P = NS).
Seven days after elastase infusion, the control group
had a statistically significant increase in aortic diam-
eter to 4.2 ± 0.2 mm as compared with 3.6 ± 0.1
mm for the BB-94 group (P = .01).
The data from this experiment also was expressed
as the percentage increase in aortic size at 7 days
after elastase infusion for each rat relative to its own
initial aortic size (Fig 1). In rats that underwent
treatment with elastase and with daily injections of
BB-94, the extent of aneurysmal dilatation was sig-
Fig 1. Comparison of increase in aortic diameter after
perfusion of rat aorta with elastase and subsequent treat-
ment with intraperitoneal injections of either carrier alone
(control group) or carrier plus BB-94. Data are represent-
ed as mean percent increase, and error bars represent stan-
dard error of mean. Data are significant at P = .026.
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nificantly reduced as compared with the rats that
were injected with vehicle alone. The treated aortas
increased in size by 113% as compared with the
157% for the control animals (P = .026).
An analysis of hematoxylin and eosin–stained
specimens revealed marked differences between the
BB-94 and control aortas. As shown in Fig 2, after 7
days, both the control rats and the rats that under-
Fig 2. Hematoxylin and eosin–stained aortic sections from rat that underwent treatment with
BB-94 (A) and control rat (B). Rat that underwent treatment shows better preservation of
medial layer and less inflammatory infiltration. Control rat shows destruction of medial layer
and transluminal infiltration of inflammatory cells. Lumen at top of photomicrographs (origi-
nal magnification, 100· ).
A
B
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went treatment with BB-94 exhibited an inflammato-
ry infiltrate. The extent of the infiltrate was reduced
considerably in the rats that underwent treatment
with BB-94 in comparison with the rats that under-
went treatment with vehicle only. There was also visi-
ble destruction of the medial layers of elastase-infused
aortas. This was consistently less extensive in the rats
that underwent treatment with BB-94. The degree of
Fig 3. Aortic sections stained with elastin stain from rat that underwent treatment with BB-
94 (A) and control rat (B). The rat that underwent treatment shows better preservation of
medial layer and significant preservation of elastin fibers as compared with control rat. Note
significant inflammatory infiltrate in control specimen. Lumen at top of photomicrographs
(original magnification, 100· ).
A
B
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medial layer disruption was not uniform along the
vessel wall circumference. It was common to find
areas of near complete disruption adjacent to areas
that exhibited essentially normal tissue architecture.
There was a correlation between the extent of local
inflammatory infiltration and vessel wall disruption.
The areas with an extensive infiltrate were highly dis-
rupted, whereas the areas that were devoid of infiltrate
were typically normal.
An analysis of elastin-stained specimens revealed a
dramatic loss of elastin fibers in the control aortas.
The extent of elastin fiber disruption was not uniform
along the vessel wall circumference. There was an
apparent correlation between the extent of local
inflammation and the loss of elastin fibers. The aortas
of the rats that underwent treatment with BB-94
showed better structural preservation of elastin fibers
as compared with the control rats (Fig 4). This was
validated with a blinded scoring of elastin staining by
five independent investigators, who demonstrated
interobserver agreement in 89% of the scores. The
discrepancies among the reviewers were, at most, in
one category. Analysis showed a significant difference
with a greater preservation of elastin content in the
rats that underwent treatment with BB-94 (P = .036).
The elastase-infused aortas also were stained with
a monoclonal antibody, MAC 1- a , that stains an
integrin subunit that is specifically expressed by neu-
trophils and monocytes. In control elastase-infused
aortas, MAC 1-a –positive cells were abundant and
penetrated the entire aortic wall (Fig 5). This MAC
1-a staining is consistent with the extensive inflam-
matory cell infiltrate that was observed with conven-
tional histologic analysis. The areas with the highest
concentration of MAC 1- a –positive cells corre-
sponded to the areas with extensive elastin degrada-
tion. In contrast, in the elastase-infused aortas of rats
that underwent treatment with BB-94, the penetra-
tion of MAC 1-a –positive cells into the aortic wall
was visibly reduced. The areas with the best preser-
vation of elastin fibers corresponded to the areas
with relatively few MAC 1-a –positive cells. 
DISCUSSION
Because MMPs play a central role in aneurysmal
development, it is only logical to try to inhibit AAA
growth with the use of MMP inhibitors. BB-94 is a
broad spectrum MMP inhibitor that has been found
to be efficacious in the inhibition of rat MMP activ-
ity. This agent has not been used previously to limit
experimental AAA development.
BB-94 significantly reduced the extent of aneurys-
mal dilatation as compared with the control group.
The treated aortas increased in size by 113% as com-
pared with 157% for the control animals (P = .026).
BB-94 treatment also resulted in a much better
preservation of elastin fibers, especially as compared
with the control animals in which there was almost a
complete destruction of elastin. BB-94 also dramati-
cally decreased the extent of inflammatory infiltration
into the aortic wall. These changes in infiltrate were
seen with the standard hematoxylin and eosin stains
and with the specific MAC 1-a antibody stain for
neutrophils and monocytes. An interesting note is the
localized nature of the elastin destruction in the areas
of increased inflammatory infiltrate.
The rat model used in this project has been well
described by other investigators and appears to
mimic the human aneurysm model in many regards.
The initiating event in the rat model is the infusion
of elastase, whereas in humans, the events associated
with triggering the development of AAA formation
are not yet understood, which represents a major
difference between the animal model and the human
disease state. After initiation, an inflammatory
response develops in the rat aortic wall.13-15
Subsequently, there is an increase in MMP activity in
the aorta16 with elastin degradation and aortic
enlargement that occurs predominantly during the
first 7 days after elastase infusion.16
Fig 4. Elastin degradation of rat aorta cross sections
shown with elastin staining (as described in methods). Bar
height represents number of rats in each category for con-
trol rats and rats that underwent treatment with BB-94.
Categories represent estimated elastin fiber content rela-
tive to amount of elastin found in normal specimen.
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Similar events have been described in the human
aortic wall with an inflammatory response especially
involving macrophages and lymphocytes.19,20
Increased MMP levels have been identified in
patients with AAAs,4 and this activity is localized to
the inflammatory cells.5,6,9 The time course of pro-
gression of the inflammatory process differs, howev-
er, between the animal model and human AAA.
With these limitations taken into consideration, the
rat elastase infusion model provides a useful tool for
testing novel drug therapies that are potentially ben-
eficial to patients with aneurysms.
Anidjar et al,12 in first describing this model,
found that the medial elastin was destroyed and
believed that the macrophages played a key role in
releasing proteolytic enzymes. Anidjar et al13 subse-
quently described a parallel time course of inflam-
matory infiltration and aneurysmal enlargement.
Halpern et al15 found a similar early inflammatory
infiltrate with subsequent dramatic loss of collagen
and elastin. These investigators demonstrated an
evolving pattern of proteinase expression and a sig-
nificant increase in macrophages and lymphocytes in
the aortic wall.
Petrinec et al16 used the rat aortic aneurysm
model to study the effects of doxycycline on the
development of aneurysms. Doxycycline has an
inhibitory effect on MMPs that is not on the basis
of its antimicrobial activity but that is through a
mechanism involving the blockade of expression of
MMPs. Doxycycline caused a significant attenua-
tion in aneurysmal dilation and a better preserved
elastin. Interestingly, doxycycline did not result in
a difference in the inflammatory response but did
Fig 5. MAC 1-a antibody staining of aortic cross sections from control rat (A and B) and rat
that underwent treatment with BB-94 (C and D). Sections from control rat show destruction
of medial layer and transmural infiltration with the MAC 1-a –staining cells as compared with
sections from the treated rat that show better preservation of medial elastin (as evidenced by
autofluorescence) and less infiltration of MAC 1-a –staining inflammatory cells. Original mag-
nification 50· (A and C) and 100· (B and D).
A B
C D
have an inhibitory effect on MMPs with decreased
levels of 92 kd MMP-9.
Indomethacin, a nonsteroidal anti-inflammatory
drug that blocks macrophage activation, has also
been shown to suppress aneurysm formation in the
rat model.21 This finding is consistent with the
results reported in this paper—that inflammatory
infiltration appears to be linked to aortic destruc-
tion. Conclusions regarding the efficacy of BB-94 as
compared with doxycycline or indomethacin in this
model cannot be made because of the variability in
the sizes of aneurysms reported, which perhaps
reflects subtle differences in surgical technique.
We found a marked decrease in the inflammato-
ry response in rats that underwent treatment with
BB-94. We also observed less inflammatory penetra-
tion of the medial layer in those rats that underwent
treatment with BB-94. As shown by the autofluo-
rescence properties of elastin, the areas of elastin
fiber destruction correlated with the areas of inva-
sion with the MAC 1-a –staining cells. These find-
ings are consistent with those of other investigators
who have implicated inflammatory cells as the
source for enzymes that lead to degradation of the
ECM and subsequent aneurysm formation.9,15-17
BB-94 may not only prevent the action of the
MMPs once it is released, but it may also affect the
migration of inflammatory cells because this move-
ment into the media may be dependent on their
ability to degrade the ECM.
In conclusion, we have demonstrated that the
competitive MMP inhibitor BB-94 was able to
attenuate aneurysmal development in the rat aortic
model. Control animals have a robust inflammatory
response in the aorta, and these inflammatory cells
are the likely source of MMPs. An unexpected con-
sequence of BB-94 treatment was the inhibition of
the inflammatory cell infiltration of the aorta. The
mechanism underlying this response is unknown.
Further studies are warranted to define the nature of
this complex process that results in aneurysm forma-
tion because the pharmacologic inhibition of MMP
activity could provide a novel nonsurgical treatment
for patients with AAA.
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Dr B. Timothy Baxter (Omaha, Neb). Dr Bigatel and
his group from the Geisinger Medical Center provide addi-
tional experimental evidence for the important role of matrix
metalloproteinase (MMP) in aneurysmal disease of the aorta.
The MMPs are a family of enzymes that are capable of
degrading all the components of the extracellular matrix.
This study uses a well-established rat model first described by
Anidjar and Dobrin in which elastase is infused with supra-
physiologic pressures inducing a secondary inflammatory
response followed by aneurysmal dilatation. After this initial
treatment, the animals were randomized to undergo treat-
ment with daily intraperitoneal injections of a nonspecific
MMP inhibitor developed by British Bio-tech versus injec-
tion of a vehicle without the MMP inhibitor. The endpoints
for this study were aneurysm size, inflammatory infiltrate,
and degree of elastin degradation. The data show a signifi-
cant decrease in aneurysm size of the MMP-treated group
with relative elastin preservation and inhibition of the inflam-
matory infiltrate. This latter finding, the inhibition of the
inflammatory infiltrate, is significant in that this was not
observed in the previous studies with this model with anoth-
er nonspecific MMP inhibitor—doxycycline. One of the
potential mechanisms for this decrease in inflammation is the
inability of the inflammatory cells to enter the matrix when
they are not producing the MMPs. Another potential mech-
anism in this study, because the drug was given intraperi-
toneally, is that the peritoneal macrophages were inhibited
by the local drug concentrations.
I had the opportunity to review the manuscript and
received it in a timely fashion, and I have several specific
questions for the authors.
1. Because you did attempt to develop a quantitative
analysis for elastin degradation, did you also attempt
to do this for inflammatory infiltration? Did you use a
specific protocol for determining the number of sec-
tions that would be analyzed for comparison of the
elastin and the inflammatory infiltrate? I raise this
question because you conclude that there is a signifi-
cant decrease in the inflammatory infiltration but also
indicate that there is a high degree of variability with-
in the sections. Thus, it would be valuable to quanti-
fy your impressions to exclude the possibility of a bias.
2. Could you speculate as to why the group that
underwent treatment with BB-94 had little appar-
ent inflammation and yet so much aneurysmal
dilatation? Does this simply represent a component
of injury associated with the direct infusion?
3. Finally, did you use doxycycline? Perhaps you could
comment on the potential toxicity associated with
these metalloproteinase inhibitors.
In conclusion, there are several important observa-
tions as we work toward the goal of developing a clinical
trial for inhibiting the growth of small aneurysms. We all
know that these aneurysms are easily detectable, but
screening is currently not considered cost-effective
because there is no medical means to inhibit growth. As
the current generation of baby boomers moves into the
next decade, aneurysms will become common. And
although these techniques that we are developing may
help in making aneurysm treatment less morbid, there is
still a significant morbidity and mortality associated with
repair. All of these statistics underline the importance of
making every effort to understand this complex disease
process and develop pharmacologic strategies.
I would like to congratulate Dr Bigatel and his group,
and I thank you for allowing me to discuss this paper.
Dr David A. Bigatel. Thank you, Dr Baxter, for your
insightful comments. I will try to answer your questions.
We did not specifically quantitate the inflammatory
infiltrate in these specimens. However, there was a direct
correlation between the areas of the inflammatory infiltrate
and the areas of elastin degradation. So, a scale similar to
what we are showing would probably be representative of
what we had seen because those areas where there was
complete elastin degradation had the greatest infiltration of
the inflammatory cells. And in areas where there was pre-
served elastin, we did not see the inflammatory cells.
As far as the number of sections that we used for this,
all of the rats in this study had both hematoxylin and eosin
staining and the MAC 1-a staining. We did not attempt to
divide out the specimens or select the specimens in any
form. So, all of the rats had the same analysis performed.
Your second question asked why, if there is less inflam-
mation in the treated rats, did we still see enlargement. We
looked at all of the specimens, and we observed that there
were areas of patchy preservation and patchy degradation
of elastin fibers, with those that were in the control group
having the greatest amount of degradation and being clos-
er to the complete level of degradation. So, one of the rea-
sons that I think there was still aneurysmal dilatation is
that there still are areas of the wall that do have elastin
fiber breakdown.
Your last question addressed whether we looked at
doxycycline. We did not reproduce those experiments.
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Dr Ronald L. Dalman (Palo Alto, Calif). I would like
to congratulate the authors for obtaining important results
with a difficult experimental model. We recently have
shown limitation of flow-mediated aortic enlargement in a
rat femoral arteriovenous fistula with a different MMP
inhibitor, RS 113456 (Roche Bioscience, Palo Alto, Calif).
My question is—it is known that some MMP
inhibitors reduce blood pressure over time. I am curious
whether, in your model, you controlled for blood pressure
or heart rate in the two groups because chronic hypoten-
sion would provide an alternative explanation for the
results that you demonstrated.
Dr Bigatel. We did not measure those parameters.
Dr Christopher K. Zarins (Stanford, Calif). I think it
is interesting that you found that the inflammatory
response was diminished. Have you done any studies in
which you focused on specifically limiting the inflammato-
ry response alone? Do you have any idea what that might
do to the aneurysm enlargement?
Dr Bigatel. There have been some studies in the liter-
ature—we did not do these studies ourselves—that have
looked at methylprednisolone and cyclosporine, and they
showed a similar type of response in which the aneurysmal
dilatation was less in those animals that were treated.
CORRECTION
Fig 2 was incorrectly printed by the Journal of Vascular Surgery in the October 1998 article entitled
“‘Marsupial cava’ and ruptured abdominal aortic aneurysm: A case report and review of the literature” by
Alessandro Schiavetta, MD, et al (J Vasc Surg 1998;28:719-22). The figure was printed in reverse of the
author’s intentions. The correct figure and legend appear below. 
Fig. 2. Anatomic relationships of marsupial cava.
